Cary, NC, Jan. 12, 2022 (Globe NEWSWIRE) — APIE Therapeutics, a preclinical biopharma company groundbreaking microvasculature endothelium drug improvement by focusing on the apelin receptor (APJ), declared the appointments of Debra K. Bowes, MBEE and Seth Hetherington, M.D. to the positions of chief small business officer and chief health-related officer, respectively. The two are seasoned executives with in depth practical experience attained over numerous decades at large pharmaceutical providers as very well as tiny biotechnology firms.
“Debra and Seth be a part of APIE at a essential time in our development as we make plans to advance our 1st program into the clinic and assess our pipeline for potential development opportunities,” spelled out Esther M. Alegría, Ph.D., founder and CEO of APIE Therapeutics, “We’ll look to Seth’s expertise as we full our IND-enabling do the job for APT-101 and prepare to begin a scientific trial in clients with systemic sclerosis (SSc), including these who have progressed to interstitial lung ailment (SSc-ILD). Furthermore, Debra’s keen organization acumen will be invaluable as we evaluate possibilities to leverage our technology and prioritize our pipeline to improve our probable for achievements and very long-term expansion. Needless to say, their appointments incorporate vital abilities to the APIE leadership team and put us on robust footing to meet up with our aims in 2022.”
Ms. Bowes will come to APIE adhering to 30-a long time in the lifetime sciences, through which time she has properly concluded extra than 100 biotech/pharma licensing specials. She was most lately the founder and CEO of Chevy Chase BioPartners (CCBP), a consulting and advisory agency specializing in industrial strategic planning, licensing and funding for biotechnology and pharmaceutical providers. Ms. Bowes served Maxcyte Cell Remedy as a CBO , the place she constructed their drug improvement crew, filed the company’s initially investigational new drug (IND) software, initiated their very first medical demo and negotiated a few licensing agreements. She served in senior business advancement positions at MedImmune, Amylin Pharmaceuticals and Pfizer, in which she managed licensing and new products preparing for oncology. Earlier, as around the globe market place supervisor for Centocor (a Johnson & Johnson enterprise), Ms. Bowes was responsible for growing licenses in Europe and Asia.
In addition to her experienced responsibilities, Ms. Bowes is a national board member of Ladies in Bio and earlier acted as the organization’s countrywide president. She acquired a Master of Biotechnology Company and Entrepreneurship (MBEE) from Johns Hopkins College and a Bachelor of Science in mobile biology from the University of Cincinnati. In addition, she retains a Healthcare Technologist (M.T.) certification from the American Society of Scientific Pathologists.
In addition to his part as chief healthcare officer (CMO), Dr. Hetherington will keep on being a member of the APIE board of directors. In close proximity to term, he will be accountable for taking care of the scientific and regulatory preparations for APT-101 and developing a medical advisory committee. Dr. Hetherington has 20 several years of working experience as CMO at biotech companies most lately at ReViral Ltd., a company targeted on progress of novel antiviral therapeutics. Prior to joining ReViral, Dr. Hetherington was the CMO at Genocea Biosciences, Cambridge, MA, the place he led the scientific development of therapeutic vaccines. Dr. Hetherington served as senior vice president of clinical and regulatory affairs at Icagen, Inc., RTP, NC. Prior to Icagen, Dr. Hetherington served as vice president, medical progress and CMO at Inhibitex Inc., in Alpharetta, GA. He held a variety of positions of rising responsibility in in HIV scientific progress at GlaxoSmithKline from 1995 to 2002. Dr. Hetherington is an adjunct medical college member at the UNC University of Medicine and beforehand held appointments at educational healthcare facilities, which include the University of Tennessee, St. Jude Children’s Study Hospital, Memphis, TN, and Albany Clinical College, Albany, NY.
Dr. Hetherington earned his B.S. at Yale University and his M.D. at the College of North Carolina, Chapel Hill. He accomplished his residency instruction in pediatrics at the College of North Carolina and completed a fellowship in pediatric infectious ailments at the College of Minnesota. Dr. Hetherington has posted extensively in clinical and scientific literature, and is board certified in both equally pediatrics and pediatric infectious conditions. He has served as the marketplace agent to the Vaccines and Related Blood Products and solutions Advisory Committee of the Fda, the Countrywide Vaccine Advisory Committee of the U.S. Division of Health and Human Products and services, and numerous advert hoc critique committees of the NIH.
About APIE Therapeutics
APIE Therapeutics is a preclinical stage biopharmaceutical organization revolutionary the growth of a portfolio of little-molecule therapeutic medications that focus on the apelinergic signaling pathway to restore and regenerate, submit damage, the vasculature market, which is involved precursor of lots of persistent and fibrotic disease’s pathophysiology. APIE Therapeutics accredited a portfolio of in excess of 800 compounds from RTI Intercontinental, a nicely-identified nonprofit analysis institute and inventors of industrial medicines these types of as Taxol®, Camptothecin®, EllaOne® and Esmya®.
The company’s guide applicant, APT-101, is at IND-enabling stage. The enterprise is on observe to file an IND application with the U.S. Food stuff and Drug Administration to commence a clinical program for the treatment method of patients with systemic sclerosis (SSc), together with these who have progressed to interstitial lung condition (SSc-ILD). Systemic sclerosis, occasionally referred to as systemic scleroderma, is a progressive systemic sickness of unknown result in characterized by fibrotic scaring in major organ devices which includes the pores and skin and kidneys. Individuals usually development to acquire interstitial lung illness (ILD), which is the primary result in of early dying for sufferers with SSc. Now, systemic sclerosis sufferers identified with ILD confront an estimated 5-12 months life expectancy from analysis. The two accepted medicines supply constrained gain with safety/tolerability concerns, as a result symbolizing a significant health-related unmet want.
APIE Therapeutics Esther Alegria, Ph.D. [email protected]
Copyright 2022 GlobeNewswire, Inc.